Chemical Nameoritavancin
Dosage FormInjection (intravenous; 400mg)
Drug ClassAntibacterials
CompanyMelinta Therapeutics Inc.
Approval Year2014


  • For the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Orbactiv (oritavancin) Prescribing Information2014Melinta Therapeutics Inc., Lincolnshire, IL